Drug Research Continues for Gluten Consumption of Celiac Patients

Scientists, celiac disease, and people with gluten intolerance continue to work on drugs to consume gluten-rich foods. According to a report published in the Journal of American Society, an enzyme has been developed that breaks down the gluten building stones to prevent inflammation and other undesirable symptoms that occur in the intestines.

In celiac disease, the consumption of gluten-containing foods such as wheat, barley and rye results in inflammation in the digestive tract, which results in a number of undesirable symptoms. Some enzymes on the surface are breaking up gluten into smaller peptides. Although these peptides are harmless components for many people, they cause triggering of autoimmune reactions in gluten intolerance or celiac disease when they pass into the small intestine. The only solution to this undesirable situation is to consume gluten-free foods. In addition, no definitive treatment for celiac disease or medication has been developed.


But nowadays research continues, scientists have discovered that a natural enzyme can disintegrate peptides that result from the breakdown of gluten. This enzyme has undergone alteration in laboratory conditions to obtain a precisely targeted component. The enzyme, which can break down and inactivate up to 95% of gluten peptides, is called "KumaMax." Researchers are hopeful that KumaMax can be made ideal by being developed and studied, and now celiac disease patients can also consume gluten products.